Community Access & AI: Dr Danny Nguyen on the Future of Lung Cancer Care

In this episode of The OncoloGIST, Dr Danny Nguyen, assistant clinical professor at City of Hope in Orange County, explores the rapidly evolving landscape of clinical trials and thoracic oncology. Dr Nguyen highlights a vital shift in the field: the movement of clinical trials from restricted academic centers into the community. He shares his motivation for this transition, noting that logistical barriers like traffic, parking, and insurance often prevent patients from accessing life-saving research in city centers.

The conversation delves into the "multi-faceted approach" required to make community trials successful, emphasizing that while site infrastructure must be robust, trial sponsors must also have the "leap of faith" to partner with community practices. Dr Nguyen also discusses the burgeoning role of artificial intelligence (AI) in oncology, specifically how AI is being utilized for more efficient site selection, patient prescreening, and predicting treatment responses to improve practical outcomes.

Turning to clinical updates, Dr Nguyen reflects on a "blockbuster" year for lung cancer. He reviews a wave of significant 2024 and 2025 approvals.

A key highlight of the interview is the discussion of the COPERNICUS trial (NCT06667076), which is intentionally lowering traditional barriers to entry—such as strict kidney function and white cell count requirements—to ensure trial populations reflect the real-world patients doctors see every day.

Finally, Dr Nguyen addresses the "last resort" stigma surrounding clinical research. He encourages providers to educate patients that trials are not just for when options run out, but are often a proactive, high-quality treatment path that can offer better results than the current standard of care.